** Shares of obesity drugmakers gain premarket after Pfizer PFE.N says it has discontinued development of experimental weight-loss pill danuglipron
** Eli Lilly LLY.N shares up 1.69% to $744.82 in premarket trading, while U.S. listed shares of Danish drugmaker Novo Nordisk NOVOb.CO rise 3.74% to $67.15
** Shares of obesity drug developer Viking Therapeutics VKTX.O jump 19.1% to $26.47, while Altimmune ALT.O rises 2.95% to $4.54
** Pfizer shares down marginally at $21.75 before the bell
** Up to last close, LLY down ~5%, VKTX down ~45%, while ALT down 39% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.